The development of the pharmaceutical industry will not only promote the improvement of the people's medical service level, but also stimulate economic growth. At a time when medical demand is getting higher and higher, the pharmaceutical industry has become one of the key industries in China. In this year, many places have set development goals for the pharmaceutical industry, together to see the specific situation.

Huzhou strives to complete the investment of biomedical industry over 4 billion yuan

Recently, Huzhou held a plenary meeting of the Biomedical Industry Promotion Group. The meeting clearly stated that it should be bigger and stronger, and strive to increase the value-added of the biomedical industry by 10%. The main business income will reach 35 billion yuan. The “Great and High” project has completed more than 4 billion yuan of industrial investment in the whole year; strives to build 5 provincial-level R&D institutions and more than 100 provincial-level R&D institutions and more than 100 provincial-level new products. 250 invention patents.

In addition, Huzhou will further carry out research on biomedical industry and introduce Huzhou Biomedical Industry Development Plan, which will focus on the long-term development goal orientation, development strategy, functional division and spatial layout of the industry. Promote the development of the bio-pharmaceutical industry by accelerating the establishment of investment promotion institutions for the bio-pharmaceutical industry and introducing leading enterprises and projects.

Yantai strives to exceed 80 billion yuan in the total output value of the pharmaceutical health industry during the year

In 2017, the total income of the pharmaceutical industry in Yantai reached 73.6 billion yuan. In 2018, Yantai will aim to build an international life science innovation demonstration zone, increase policy support and guidance of the pharmaceutical health industry, and upgrade the level and level of the pharmaceutical health industry, and strive to exceed 80 billion yuan in the total output value of the pharmaceutical health industry during the year. .

In addition, the author understands that by the end of the “Thirteenth Five-Year Plan”, the income from the main business of Yantai Medical and Health Industry will exceed 100 billion yuan, with an average annual growth rate of over 15%. Before 2020, strive to have more than 10 new drugs listed at home or abroad. The pharmaceutical health industry is also expected to become a pillar industry in Yantai City.

Taizhou strives to exceed 300 billion yuan in the scale of the big health industry in 2018

The author has learned that more than 900 well-known medical and health enterprises at home and abroad have settled in China Medical City. Taizhou City is also relying on the development advantages of the pharmaceutical industry in the whole province, actively promoting the implementation of a number of large health industry projects, and actively creating distinctive Chinese medicine tourism products, in order to achieve a perfect superposition of tourist attractions and TCM health functions.

According to relevant personnel, Taizhou City will do a good job in the pilot development of large-scale health industry clusters, accelerate the expansion of the entire industry chain of “medicine, medicine, nutrition, food and tourism” and strive to exceed 300 billion yuan in the scale of the big health industry in 2018. With the release of the "Taizhou City Health Industry Agglomeration Development Plan", the development of Taizhou City's big health industry will become more and more clear.

Haikou strives to exceed 20 billion yuan in output value of the pharmaceutical industry this year

The Haikou pharmaceutical industry has set a development goal. In 2018, Haikou City will enlarge and strengthen the pharmaceutical industry, accelerate the layout of medical devices, biomedicine and marine bio-pharmaceuticals, introduce leading pharmaceutical companies and research institutions at home and abroad, and strive to promote the transformation of national major new drug creation results and strive for the output value of the pharmaceutical industry. Breaking through 20 billion yuan.

In recent years, the pharmaceutical industry in Haikou has developed rapidly. In 2017, Haikou's pharmaceutical industry achieved rapid growth, accelerated internationalization, enhanced innovation, and outstanding results. It is believed that under the policy support, the efforts of leading enterprises and the continuous development of innovative technologies, Haikou's pharmaceutical industry will achieve a new leap.

Surfactants

We adopt a comprehensive classification method, which is divided by the ionicity of surfactants as follows which can all be provided by Insen Biotech: 1. Anionic surfactant: stearic acid, sodium dodecylbenzene sulfonate. 2. Cationic surfactant: quaternary ammonium compound. 3. Zwitterionic surfactants: lecithin, amino acid type, betaine type. 4. Non-ionic surfactants: fatty acid glycerides, fatty acid sorbitan (Span), polysorbate (Tween).

Surfactant Agent ,Carbomer 940 Powder,Surfactant Cosmetic ,Nonionic Surfactant

Hunan Insen Biotech Co., Ltd , https://www.insenhealth.com